Hrt Financial LP Cytom X Therapeutics, Inc. Transaction History

Hrt Financial LP

$15.7 Billion
Q4 2024

A detailed history of Hrt Financial LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 110,242 shares of CTMX stock, worth $90,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,242

Previous 26,840 310.74%

Holding current value

$90,398

Previous $31,000 264.52%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.29 $71,725 - $107,588	83,402 Added 310.74%	110,242 $113,000
Q3 2024 Nov 12, 2024	BUY	$1.12 - $1.51 $30,060 - $40,528	26,840 New	26,840 $31,000
Q1 2024 May 13, 2024	BUY	$1.41 - $2.74 $23,731 - $46,116	16,831 New	16,831 $36,000
Q2 2022 Aug 12, 2022	SELL	$1.53 - $2.89 $104,436 - $197,268	-68,259 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $202,655 - $355,216	-75,901 Reduced 52.65%	68,259 $182,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $19,411 - $37,068	-5,016 Reduced 3.36%	144,160 $624,000
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $644,440 - $959,201	149,176 New	149,176 $759,000
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $182,424 - $248,760	-27,640 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $34,821 - $42,517	5,382 Added 24.18%	27,640 $181,000
Q3 2020 Nov 13, 2020	BUY	$6.55 - $8.83 $145,789 - $196,538	22,258 New	22,258 $148,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $66,705 - $158,910	-18,478 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $95,531 - $164,638	18,478 New	18,478 $153,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

46.1M

Call Options Held

3.7K

Put Options Held

4.7K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $54.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account